Glycaemic Effects of Non-statin Lipid-Lowering Therapies - Test2 - elhamkhani - TriplyDB

Glycaemic Effects of Non-statin Lipid-Lowering Therapies

Glycaemic Effects of Non-statin Lipid-Lowering Therapies

http://www.wikidata.org/entity/Q28070152

about

Glycaemic Effects of Non-statin Lipid-Lowering Therapies

http://www.wikidata.org/entity/Q28070152

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Glycaemic Effects of Non-statin Lipid-Lowering Therapies

@ast

Glycaemic Effects of Non-statin Lipid-Lowering Therapies

@en

Glycaemic Effects of Non-statin Lipid-Lowering Therapies

@nl

type

label

Glycaemic Effects of Non-statin Lipid-Lowering Therapies

@ast

Glycaemic Effects of Non-statin Lipid-Lowering Therapies

@en

Glycaemic Effects of Non-statin Lipid-Lowering Therapies

@nl

prefLabel

Glycaemic Effects of Non-statin Lipid-Lowering Therapies

@ast

Glycaemic Effects of Non-statin Lipid-Lowering Therapies

@en

Glycaemic Effects of Non-statin Lipid-Lowering Therapies

@nl

P1433

Q28070152-604E1BE5-D79E-42DB-BFD5-D8029437AC2A

P1476

Q28070152-0E852B4D-19DC-4C24-AB25-C7663651326F

P2093

Q28070152-B1B33F71-243D-40B6-969B-F0FD54C3CAAC

Q28070152-BDC205B2-4D00-48EA-8F33-AC3B52881774

P275

Q28070152-8F7DC1C1-8934-4802-A72B-2C8D6AFB0EAA

P2860

Q28070152-039E3099-F5D9-4B1A-8A80-F7EA517825E8

Q28070152-04214A15-F4D8-458D-A746-BA3FB994FA4F

Q28070152-13BC855E-FDC9-49F9-B1FF-F56FE559922D

Q28070152-1C71127A-2CBC-4876-8DAE-3AB3FA916163

Q28070152-34149647-FD37-416C-AB2B-8CABAD1492AB

Q28070152-3D209473-E6AD-40A0-9B25-FBD613AB3437

Q28070152-3D5F2BE8-5AE2-4D57-B5F2-ABC5EF531783

Q28070152-4D92935E-6F19-467B-A09E-B08CB2BDADC4

Q28070152-50A589E3-2DDC-4B38-8E54-35368B73E8F6

Q28070152-5769458D-C03C-48C0-866F-0159BC3EBD33

P2888

Q28070152-02EB2DDD-E963-4525-9344-76A49B85181B

P304

Q28070152-14AAF651-31B9-46DE-A711-58E892B73765

P31

Q28070152-019B21E1-CF6B-4305-B1E8-D032B6F5274D

Q28070152-06FAB619-DC86-4723-8266-25E050BBAC5B

P356

Q28070152-DBAE1032-602D-43C1-9E99-27B99C595B4A

P407

Q28070152-2D38F16E-B0BE-446C-9E93-6E9914D269F7

P433

Q28070152-02EC272F-C29E-4AA4-A3D9-B774CE03E65C

P478

Q28070152-9CEF6DEF-1053-4B0B-86B0-9F9AB0473D22

P5008

Q28070152-F1654046-A671-437C-90D6-AFB0298F2A43

P577

Q28070152-2CA6AFBB-C40F-4A27-929D-C80F3D495A5A

Q28070152-A42F67F2-4A5E-42D2-B159-DDF78482C9C1

P6179

Q28070152-08B5CD3A-1EE9-4F91-A5A4-13DC9B5581AB

P698

Q28070152-EEDDBE43-779A-4F44-932E-F1ACC17A4BF0

P921

Q28070152-2B5B73FB-0CB3-4AEA-A3FB-4761BB130C98

Q28070152-5583FB9E-A87F-4D96-B6D0-7FFC2420A94D

Q28070152-729A3DAC-BB04-44F9-A9F2-3F21F34E0026

Q28070152-BAC57FBB-7001-4812-8278-AAA1FB776361

Q28070152-E192F11C-6C72-4E3C-BCA7-E0C6F7B05188

Q28070152-FE8A5A0B-2503-45C4-99BA-92A1C821ED96

P932

Q28070152-36D75427-3977-4CEF-9CDA-CB408448D2CC

P356

S11886-016-0795-9

P1433

Current cardiology reports

P1476

Glycaemic Effects of Non-statin Lipid-Lowering Therapies

@en

P2093

Naveed Sattar

http://www.w3.org/2001/XMLSchema#string

Patrick D. Collins

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

P2888

s11886-016-0795-9

P304

133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11886-016-0795-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009870945

http://www.w3.org/2001/XMLSchema#string

P698

27864787

http://www.w3.org/2001/XMLSchema#string

P921

Angliavandeniai

type-2 diabetes

mechanism of action

diabetic angiopathy

maturity-onset diabetes of the young

P932

5116040

http://www.w3.org/2001/XMLSchema#string